IPP Bureau
Healthium launches Theruptor Novo for diabetic foot ulcers
By IPP Bureau - October 11, 2022
Theruptor Novo is a best in class patented product which provides an optimum healing environment and addresses the concerns of chronic wound dressing
Ashland announces Klucel xtend HPC matrix former for extended-release tablets
By IPP Bureau - October 11, 2022
The need for hot-melt extrusion (HME) polymers is expected to grow as the pharma industry moves to implement more continuous and sustainable processes.
Universal COVID-19 vaccine can be game-changer for developing countries like India, says GlobalData
By IPP Bureau - October 11, 2022
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Merck announces positive top-line results from Phase 3 Stellar Trail evaluating Sotatercept for the treatment of PAH
By IPP Bureau - October 11, 2022
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
India committed to promote green and climate resilient healthcare facilities: Dr Pawar
By IPP Bureau - October 09, 2022
Cumulatively, almost 75% of the health centres in the country have been electrified with a cumulative solar capacity of 3.5 MW
AIIA signs MoU with AIST
By IPP Bureau - October 09, 2022
The MoU will enable both countries to promote research collaboration and building capacities in the field of the Indian Ayurvedic system of traditional medicines
Biocon Foundation receives Mahatma Award 2022
By IPP Bureau - October 09, 2022
The award was presented to Biocon Foundation as a mark of recognition of various projects undertaken during the year for reducing the environmental impact on cities
Lupin partners global Agencies to support tuberculosis prevention treatment
By IPP Bureau - October 09, 2022
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
Nureca's subsidiary receives ISO 13485 certification for Indian medical device facility
By IPP Bureau - October 09, 2022
The certification will open new avenues for our flagship brand “Dr Trust”, enabling them to export these devices to many more countries
Thermo Fisher Scientific emphasizes on the need for more disruptive technologies
By IPP Bureau - October 09, 2022
Thermo Fisher is working closely with large pharmaceutical businesses to develop companion diagnostics in multiple areas such as heart disease, neurosciences and infectious diseases.
Dipharma receives regulatory authorization for the new line at Its cGMP pilot plant
By IPP Bureau - October 09, 2022
The company increases its efficiency and is able to face the growing demand for its services.
LISSUN announces 2nd edition of its campaign -'#LISSUNToYourMind'
By IPP Bureau - October 09, 2022
Campaign to celebrate World Mental Health Day theme "Mental Health in an Unequal World"
Pfizer acquires Global Blood Therapeutics
By IPP Bureau - October 09, 2022
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
Pfizer announces positive topline results from Phase 3 TALAPRO-2 trial
By IPP Bureau - October 09, 2022
Study achieves primary endpoint of radiographic progression-free survival
BioMarin simplifies organizational structure to increase efficiency
By IPP Bureau - October 09, 2022
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
